Perhaps it is because high-risk women without an identified mutation are, on average, at lower lifetime risk for breast cancer (30–40%) than BRCA1 and BRCA2 mutation carriers (60–80%) and thus the balance of risks and benefits is assessed differently. This evidence concerns the gene BRCA1 and breast cancer.